Galapagos NV (NASDAQ:GLPG) Given Average Recommendation of “Hold” by Analysts

Galapagos NV (NASDAQ:GLPG) has been assigned an average recommendation of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $36.50.

Several analysts have issued reports on GLPG shares. Weiss Ratings raised shares of Galapagos from a “sell (d)” rating to a “hold (c)” rating in a research note on Thursday, February 26th. Raymond James Financial reissued a “market perform” rating on shares of Galapagos in a research note on Tuesday, February 24th. UBS Group reissued a “market perform” rating on shares of Galapagos in a research note on Tuesday, February 24th. Royal Bank Of Canada raised their price objective on shares of Galapagos from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research note on Tuesday, February 24th. Finally, Wall Street Zen raised shares of Galapagos from a “hold” rating to a “buy” rating in a research note on Saturday, March 28th.

Institutional Trading of Galapagos

Several institutional investors have recently added to or reduced their stakes in GLPG. State of Wyoming bought a new stake in Galapagos in the second quarter worth about $28,000. GAMMA Investing LLC raised its stake in shares of Galapagos by 79.4% during the third quarter. GAMMA Investing LLC now owns 1,473 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 652 shares in the last quarter. Van ECK Associates Corp raised its stake in shares of Galapagos by 61.6% during the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 750 shares in the last quarter. Arax Advisory Partners raised its stake in shares of Galapagos by 319.2% during the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after acquiring an additional 1,778 shares in the last quarter. Finally, Quadrant Capital Group LLC bought a new stake in shares of Galapagos during the third quarter valued at approximately $134,000. Institutional investors own 32.46% of the company’s stock.

Galapagos Trading Down 1.6%

GLPG opened at $28.93 on Wednesday. The firm has a market cap of $1.91 billion, a P/E ratio of -18.43 and a beta of 0.32. Galapagos has a 12 month low of $23.23 and a 12 month high of $37.78. The stock has a 50-day moving average of $32.61 and a 200 day moving average of $32.63.

Galapagos (NASDAQ:GLPG) last announced its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share (EPS) for the quarter. The firm had revenue of $1.06 billion during the quarter. On average, research analysts forecast that Galapagos will post -1.6 earnings per share for the current fiscal year.

Galapagos Company Profile

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.